- Aditxt, Inc. ADTX stock is surging Thursday as it expands its portfolio to include innovative therapies for infectious diseases.
- ADTX inked an asset purchase agreement with Cellvera to acquire a 50% stake in G Response Aid FZE (GRA or Global Response Aid) for $24.5 million.
- The remaining 50% is owned by global logistics company Agility, Inc.
- Based in Dubai, Global Response Aid, was established to address the market challenges created by the COVID-19 pandemic and other threats to public health.
- Together with Dr. Reddy's Laboratories Ltd RDY, GRA holds an exclusive, worldwide license for Avigan 200mg, excluding Japan, China and Russia.
- With the acquisition deal, Aditxt will gain the rights to manufacture and market the broad-spectrum antiviral drug Avigan. The deal could drive Aditxt's strategic revenue and growth.
- This agreement is a significant step for Aditxt as it expands the company's portfolio to include innovative therapies for infectious diseases.
- Price Action: ADTX shares are trading higher by 12.8% at $0.97 on the last check Thursday.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in